PureTech
Developing and commercializing highly differentiated medicines for devastating diseases.
HQ location
Boston, United States
Website
Launch date
Employees
Market cap
$427m
Enterprise value
$89m
Share price
£1.26 PRTC.L
Notable known LPs
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $11.4m | Grant | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 2419 % | (47 %) | (4 %) | 20 % | (79 %) | (64 %) | 475 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (399 %) | (1092 %) | (1735 %) | (2153 %) | (9699 %) | (17641 %) | (2423 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (267 %) | 4847 % | 72 % | (607 %) | (2409 %) | (8760 %) | 1240 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 350 % | 750 % | 734 % | 817 % | 5556 % | 9831 % | 1258 % |
Source: Company filings or news article
Related Content
Notes (0)
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Country
By Industry
Investments by PureTech
Edit
ACQUISITION by Bristol-Myers Squibb Dec 2023
exited
ACQUISITION by PureTech Jun 2021